Choosing the Right Radiopharmacy Partner for Therapeutic Commercialization
Back to Industry Insights / How to Choose the Right Radiopharmacy
How to choose the right radiopharmacy partner for successful therapeutic radiopharmaceutical commercialization
Your therapy may be groundbreaking, but without the right radiopharmacy partner, commercialization can quickly become your greatest challenge. Learn the eight critical capabilities manufacturers should evaluate to reduce risk, accelerate launch, and reliably deliver therapies to patients.
Your commercialization strategy needs more than a distributor
Therapeutic radiopharmaceuticals are transforming oncology research and care. Yet supply chain fragility, regulatory gaps, logistics breakdowns, and inadequate infrastructure can delay launches, erode physician confidence, and leave patients waiting.
This guide gives manufacturers a rigorous, practical framework for evaluating radiopharmacy partners. It moves beyond marketing claims to the operational realities that determine whether your therapy reaches the patients who need it—on time, patient-ready, and at scale.
Commercializing radioligand therapies requires a new operational model
Cancer incidence continues to rise globally, driving unprecedented demand for precision tools. Theranostics—pairing diagnostic imaging with targeted radionuclide therapy—has emerged as one of the most powerful advances in modern oncology. Agents such as lutetium-177-based therapies and next-generation PET tracers are delivering meaningful clinical benefit in prostate cancer, neuroendocrine tumors, and expanding indications.
However, this transformation demands an entirely different commercialization model.
- Short half-lives leave no margin for error. Complex handling requirements, strict compliance, radioactive waste management, and the need for rapid, temperature-controlled delivery create a uniquely demanding environment.
- Growth can quickly expose operational gaps. Insufficient geographic reach, limited capacity, or inconsistent site support can delay treatment and constrain market access.
- Commercial scale depends on coordinated infrastructure. Manufacturers need a partner that can synchronize production, patient scheduling, dose preparation, and last-mile delivery across multiple treatment sites.
8 Factors to Consider When Selecting a Radiopharmacy Partner for Therapeutic Commercialization and Clinical Development.
Get the complete evaluation framework, detailed questions to ask potential partners, and practical guidance for aligning radiopharmacy capabilities with your commercialization timeline.
"*" indicates required fields
Frequently Asked Questions
Manufacturers should assess eight critical factors: proven therapeutic experience, geographic scale, regulatory readiness, time-critical logistics, end-to-end operational support, waste management capabilities, performance and quality metrics, and partnership flexibility. These elements determine whether a therapy can move reliably from manufacturing to patient administration.
Therapeutic radiopharmaceuticals have short half-lives and require rapid, reliable delivery. A partner with broad U.S. geographic scale—covering major oncology markets and community sites—reduces secondary pharmacy reliance, minimizes delays, and expands patient access. Networks limited to a few regions create access gaps that can stall commercial uptake.
Partners must demonstrate full compliance with USP <825>, 21 CFR Part 212 (for PET), state board of pharmacy rules, and NRC/Agreement State requirements. Experience navigating multi-state licensing and inspection readiness is essential for smooth commercial launches across the United States.
A strategic partner delivers more than doses. It supports site activation, clinical education, just-in-time inventory, technical consultation, performance transparency, and flexible scaling. Treating radiopharmacy selection as a simple procurement decision risks launching therapies that cannot reliably reach patients.
Yes. Jubilant operates the second-largest radiopharmacy network in the U.S and continues to expand. The network serves 1,800+ hospitals and healthcare providers and delivers more than 3 million doses annually.
Yes. Jubilant’s network handles a full continuum of SPECT and PET diagnostic agents as well as therapeutic radiopharmaceuticals, including experience with complex agents and higher-activity preparations, under rigorous quality systems aligned with USP and applicable FDA standards.
Related Resources
Therapeutic
Products
PET
Products
Product
Portfolio
Sales
& Support
Therapeutic
Products
PET
Products
Product
Portfolio
Sales
& Support
Contact Us
To learn more about our portfolio and services, fill out the form to speak with a sales representative.
Contact Us
Reach out to Jubilant Radiopharmacies through our Contact Us form for inquiries, support, and more.